SCHEMBL9647584

SCHEMBL9647584

C=C(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)/C=C\C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 4/20 0.62
▸ PGR P06401 12/20 0.58
▸ NR3C1 P04150 13/20 0.58
▸ ESR1 P03372 2/20 0.57
▸ ESR2 Q92731 2/20 0.57
▸ THRA P10827 1/20 0.57
▸ CYP3A4 P08684 3/20 0.56
▸ CYP2D6 P10635 3/20 0.56
▸ CYP2C19 P33261 3/20 0.56
▸ CYP2C9 P11712 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ TP53 P04637 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ THPO P40225 1/20 0.56
▸ KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5395107 0.93 AR (0.71) ARPGRNR3C1ESR1ESR2
SCHEMBL5395109 0.93 AR (0.71) ARPGRNR3C1ESR1ESR2
SCHEMBL9146687 0.92 AR (0.58) ARPGRNR3C1ESR1ESR2
SCHEMBL9650258 0.90 AR (0.57) ARPGRNR3C1ESR1ESR2
SCHEMBL14670184 0.90 AR (0.60) ARPGRNR3C1ESR1ESR2
Aglepristone SCHEMBL16673291 0.88 NR3C1 (0.72) ARPGRNR3C1ESR1ESR2
Aglepristone SCHEMBL2108967 0.88 NR3C1 (0.72) ARPGRNR3C1ESR1ESR2
Aglepristone SCHEMBL9849187 0.88 NR3C1 (0.72) ARPGRNR3C1ESR1ESR2
Aglepristone SCHEMBL13625155 0.88 NR3C1 (0.72) ARPGRNR3C1ESR1ESR2
SCHEMBL14670140 0.86 AR (0.56) ARPGRNR3C1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5089488-A Anticarcinogenic agents; treating glaucoma, hypertension, diabetes, insomia, osteoporosis SCHERING AKTIENGESELLSCHAFT (DE) 1992-02-18 — — US claimed
EP-0254670-B1 11-BETA-(4-ISOPROPENYLPHENYL)-ESTRA-4,9-DIENE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1989-11-15 — — EP claimed
EP-0254670-A1 11-beta-(4-isopropenylphenyl)-estra-4,9-diene, their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1988-01-27 — — EP disclosed
Send feedback